Literature DB >> 12002601

Double cancer, cholangiocellular and hepatocellular carcinomas, in the cirrhotic liver.

Takeshi Yoshikawa1, Shozo Hirota, Shinichi Matsumoto, Kenta Izaki, Tetsuya Fukuda, Kazuro Sugimura, Sakan Maeda, Hajime Kitagaki.   

Abstract

A 70-year-old male patient presented with cirrhotic liver caused by hepatitis C virus and complicated with hepatocellular carcinoma. The carcinoma was effectively treated by transarterial chemoembolization, but cholangiocellular carcinoma occurred in a different segment of the liver and rapidly grew and metastasized systemically. He died 13 months after the first admission. Double cancer of the liver is uncommon, but it must be considered in the differential diagnosis of cases of hepatocellular carcinoma associated with chronic hepatitis or cirrhosis. Failure to note the occurrence of cholangiocellular carcinoma is thought to be a diagnostic pitfall in the follow-up studies of patients with hepatocellular carcinoma.

Entities:  

Mesh:

Year:  2002        PMID: 12002601

Source DB:  PubMed          Journal:  Radiat Med        ISSN: 0288-2043


  3 in total

1.  Clinicopathological Features and Post-resection Prognosis of Double Primary Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Dong-Hwan Jung; Shin Hwang; Ki-Hun Kim; Seung-Mo Hong; Young-Joo Lee; Chul-Soo Ahn; Deok-Bog Moon; Tae-Yong Ha; Gi-Won Song; Gil-Chun Park; Eun Sil Yu; Sung-Gyu Lee
Journal:  World J Surg       Date:  2017-03       Impact factor: 3.352

2.  Synchronous development of HCC and CCC in the same subsegment of the liver in a patient with type C liver cirrhosis.

Authors:  Takuya Watanabe; Jun Sakata; Takashi Ishikawa; Yoshio Shirai; Takeyasu Suda; Haruka Hirono; Katsuhiko Hasegawa; Kenji Soga; Koichi Shibasaki; Yukifumi Saito; Hajime Umezu
Journal:  World J Hepatol       Date:  2009-10-31

3.  Perihilar cholangiocarcinoma arising in hepatitis C virus-related liver cirrhosis with hepatocellular carcinoma.

Authors:  Takahiko Fujii; Yoh Zen; Yasuni Nakanuma
Journal:  J Gastroenterol       Date:  2007-08-24       Impact factor: 7.527

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.